Media centre

All Group media enquiries should be directed to
Vanessa Maydon, Corporate Affairs Director.

Cinven Partners LLP
Warwick Court
Paternoster Square
London EC4M 7AG

Tel: +44 (0)20 7661 3325
Mob: +44 (0)7802 961 902
Email: Vanessa Maydon

Press releases

23 August 2016

Cinven to acquire Bioclinica

International private equity firm, Cinven, today announces that it has agreed to acquire Bioclinica, a global provider of clinical trial services and technology to contract research organizations (CROs) and pharmaceutical companies, based in Pennsylvania, from Water Street Healthcare Partners and JLL Partners. The consideration is not disclosed.

Bioclinica operates in a number of high growth areas to improve the efficiency and productivity of clinical trials performed around the world. This is achieved through standardisation, streamlining labor-intensive tasks and implementing technology-enabled solutions. Bioclinica benefits from structural tailwinds such as growing clinical trial activity, increased outsourcing and the adoption of clinical software services.

The Company serves more than 400 pharmaceutical, biotechnology and medical device clients through a network of offices and medical facilities in the U.S., Europe and Asia.  Bioclinica has a highly respected management team, led by CEO John Hubbard, with a long term vision to grow the business both organically and through acquisitions.

The Cinven healthcare team identified Bioclinica as a compelling investment opportunity based on its direct experience in the global clinical services market through its investment in Medpace, a leading CRO headquartered in Ohio. Cinven took Medpace public in New York earlier this month in a highly successful IPO, having acquired the business in April 2014 for a total consideration of US$915 million.

Commenting on the transaction, Alex Leslie, Partner at Cinven, said: "Cinven's global expertise, deep industry relationships and investment experience in the healthcare industry, including the CRO sector with Medpace, make us the ideal partner for Bioclinica.  This is an excellent opportunity to invest in a leading provider of technology-enabled services to the clinical trial industry with a collection of high growth businesses across the globe.  We look forward to supporting John and the exceptionally talented and experienced team at Bioclinica to develop the business in the years ahead."

Anthony Santospirito, Principal at Cinven, added: "Bioclinica is a very successful business with exciting growth opportunities. The Company's strong position in its markets will enable it to grow both organically and through targeted investment in M&A activity.  Bioclinica has already proven its ability to acquire and integrate businesses successfully, and the Cinven team intends to accelerate the Company's growth through acquisitions in the space.  Cinven is also going to work with management to support Bioclinica's expansion into Asia, with the help of our portfolio team based in Hong Kong."

John Hubbard, Ph.D., Bioclinica President and CEO, said: "We are extremely excited about this new partnership with Cinven and see great things on the horizon for Bioclinica. We experienced tremendous growth under our prior ownership and look forward to leveraging the strategic leadership and investment that will come with Cinven.  Bioclinica is on a quest to accelerate and bring clarity to clinical trials, and this move will help us to achieve these goals."

The transaction is subject to customary approvals. Jefferies LLC acted as exclusive financial advisor to Bioclinica in connection with the transaction.

Portfolio company videos

 Clinical Trials


Clinical Trials

 Travel services provider

Hotelbeds Group

Travel services provider

 Truck component manufacturer


Truck component manufacturer

 Footwear and accessories retailer

Kurt Geiger

Footwear and accessories retailer

 Contract research organisation


Contract research organisation

 Electronic security and alarm systems


Electronic security and alarm systems

 Property valuation and advisory services


Property valuation and advisory services

 Ufinet is a neutral telecom operator.


Ufinet is a neutral telecom operator.

 Business services software


Business services software

Media contacts


Vanessa Maydon
Corporate Affairs Director
Tel : +44 (0)20 7661 3325
Mob : +44 (0)7802 961 902
Email : Vanessa Maydon

Clare Bradshaw
Communications Manager
Tel : +44 (0)20 7667 3248
Mob : +44 (0)7881 918 967
Email : Clare Bradshaw

UK - FTI Consulting

Edward Bridges
Tel : +44 (0)20 7269 7147
Mob : +44 (0)7768 216 607
Email : Edward Bridges

Stephanie Ellis
Tel : +44 (0)20 3727 1173
Mob : +44 (0)7890 543 056
Email : Stephanie Ellis

France โ€“ FTI Consulting

Guillaume Granier
Tel : +33 (0)1 47 03 68 61
Mob : +33 (0)6 32 65 79 28
Email : Guillaume Granier

Caroline Guilhaume
Tel : +33 (0)1 47 03 68 17
Mob : +33 (0)6 38 91 88 51
Email : Caroline Guilhaume

Germany - FTI Consulting

Lutz Golsch
Tel : +49 (0)69 920 37 110
Mob : +49 (0)173 651 7710
Email : Lutz Golsch

Daniel Herbert
Tel : +49 (0)69 920 37 183
Mob : +49 (0)151 122 63834
Email : Daniel Herbert

US - Joele Frank

Jonathan Keehner
Tel : +1 212.355.4449
Mob : +1 917 589 2073
Email : Jonathan Keehner

Julie Oakes
Tel : +1 212.355.4449
Mob : +1 917 574 7263
Email : Julie Oakes

Spain โ€“ Groupo Albion

Alejandra Moore Mayorga
Tel : +34 91 531 23 88
Email : Alejandra Moore Mayorga

Sofia Garcia
Tel : +34 91 531 23 88

Italy โ€“ Community Group

Roberto Patriarca
Tel : +39 02 89 40 42 31
Mob : +39 335 65 09 568
Email : Roberto Patriarca

Marco Pedrazzini
Tel : +39 02 89 83 66 21
Mob : +39 347 0369 222
Email : Marco Pedrazzini